Semaglutide is a safe, doctor-prescribed GLP-1 medication that's prescribed under the brand names Wegovy®, Ozempic®, and Rybelsus®.
You can now receive this breakthrough medication in Fort Myers Florida.
Semaglutide Is A Big Deal.
Almost 70% of adults in America are obese or overweight. Obesity or being overweight is a major health problem that is linked to an increased risk
of many types of cancer as well as some of the top causes of death, such as heart disease, stroke, and diabetes. In adult individuals who were obesity or overweight,
5% to 10% weight loss with diet and exercise has been linked to a lower risk of cardiovascular disease.
Semaglutide mimics glucagon-like peptide-1 (GLP-1), a hormone that affects parts of the brain that control hunger and food intake
To lessen gastrointestinal adverse effects, the medicine dose must be raised gradually over 16 to 20 weeks to 2.4 mg once weekly.
Wegovy shouldn't be combined with other semaglutide-containing products, other GLP-1 receptor agonists, or other weight-loss treatments, whether they be prescription medications, over-the-counter medications, or herbal remedies.
Patients with a history of pancreatitis have not been studied with wegovy.
In four 68-week trials, the safety and effectiveness of Wegovy were examined. Three of the studies were randomized, double-blind, placebo-controlled trials (including dose increases every 16 weeks), and the fourth was a randomized,
double-blind, placebo-controlled withdrawal trial in which patients taking Wegovy had the option of continuing their medication or switching to a placebo. In these four investigations, Semaglutide (Wegovy), was administered to over
2,600 individuals for up to 68 weeks whereas a placebo was given to over 1,500 patients.
Participants in the biggest placebo-controlled experiment were people without diabetes.
74% of the patients were female, with an average age of 46 when the experiment began.
Body mass index (BMI) was 38 kg/m2, and the average weight was 231 pounds (105 kg).
Compared to those who received a placebo, people who received Wegovy lost an average of 12.4% of their starting weight.
Type 2 diabetic adults participated in a different trial.
51% of the population was female, with a 55-year-old median age.
Body mass index (BMI) was 36 kg/m2, and average body weight was 220 pounds (100 kg).
Compared to those who received a placebo, those who received Wegovy in this trial lost 6.2% of their starting weight.
You can take charge of your weight concerns now with the new FDA approved, doctor-prescribed, Semaglutide, now available to residents in Fort Myers, Florida.
Find Out More.